Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia

Neurobiology of Disease

Volumn 8, Issue 5, 2001, Pages 834-846

  Planas, Anna M ^a   Solé, Sònia ^a   Justicia, Carles ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Extracellular matrix; Gelatinase; Middle cerebral artery; MMP 2; MMP 9

Indexed keywords

GELATINASE A; GELATINASE B;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ZYMOGRAPHY;

EID: 0035164744     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2001.0435     Document Type: Article

References (62)

1. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS
2. Role of matrix metalloproteinase 9 after cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94
3. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40)
4. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin
5. MMP-9 (gelatinase) mRNA is expressed during mouse neurogenesis and may be associated with vascularization
6. MPP+ injection into rat substantia nigra causes secondary glial activation but not cell death in the ipsilateral striatum
7. Matrix metalloproteinases degrade myelin basic protein
8. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia
9. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions
10. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro
11. A latent Mr 94,000 gelatin-degrading metalloprotease induced during differentiation of HL-60 promyelocytic leukemia cells: A member of the collagenase family of enzymes
12. Positive and negative transcriptional elements of the human type IV collagenase gene
13. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion
14. Activation of nuclear factor-κB in the rat brain after transient focal ischemia
15. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction
16. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein
17. β-Amyloid induction of gelatinase B secretion in cultured microglia: Inhibition by dexamethasone and indomethacin
18. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons
19. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes
20. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture
21. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP1 sequences
22. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion
23. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia
24. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site
25. Matrix metalloproteinases in inflammatory demyelination: Targets for treatment
26. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
27. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors
28. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients
29. Reversible middle cerebral artery occlusion without craniectomy in rats
30. Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury-induced brain trauma
31. Matrix metalloproteinases in cerebrovascular disease
32. Identification and characterization of calcium-dependent metalloproteases in rat brain
33. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases
34. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes
35. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9
36. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states
37. Epidermal growth factor receptor in proliferating reactive glia following transient focal ischemia in the rat brain
38. Estimation of gelatinase content in rat brain: Effect of focal ischemia
39. Proteolysis of a β-peptide from Alzheimer disease brain by gelatinase A
40. Extracellular matrix-degrading proteinases in the nervous system
41. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduces infarct size
42. Injury-induced 92-kDa gelatinase and urokinase expression in rat brain
43. Matrix metalloproteinases and TIMPs are associated with blood-brain-barrier opening after reperfusion in rat brain
44. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window
45. TIMP-2 reduces proteolytic opening of the blood-brain barrier by type IV collagenase
46. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat
47. Alteration of transcription factor binding activities in the ischemic rat brain
48. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells
49. NF-kappaB is activated and promotes cell death in focal cerebral ischemia
50. Induction of matrix metalloproteinases following brain injury in rats
51. Cortical infarct volume is dependent on the ischemic reduction of perifocal cerebral blood flow in a three-vessel intraluminal MCA occlusion/reperfusion model in the rat
52. 73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation
53. Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia
54. Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells
55. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9 to extend their processes along an astrocyte extracellular matrix
56. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum
57. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo
58. Matrix metalloproteinases and their inhibition in connective tissue remodeling
59. SV40-transformed human lung fibroblasts secrete a 92-kDa typeIV collagenase which is identical to that secreted by normal human macrophages
60. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1
61. Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration
62. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification